Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now leads a fast-growing market for GLP-1 and metabolic therapies.

Modern weight-loss medications like Ozempic and Mounjaro, originally for diabetes, are gaining attention for their ability to ...

Eli Lilly’s anti-obesity and diabetes drug Mounjaro has become the No. 1 brand by sales value in the Indian Pharmaceutical Market (IPM) for the first time in the month of October. The drug clocked ...

Eli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps control blood sugar and slows digestion. Demand for such ...

Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in ...

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind ...

Eli Lilly's diabetes and obesity drug Mounjaro (Tirzepatide) has become India's top-selling drug by value for October 2025, ...

Meghan Trainor is reclaiming her health and body after a gestational diabetes scare during pregnancy. She's now strength ...

HYDERABAD, Nov 7 (Reuters) - Eli Lilly's (LLY.N), opens new tab weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, overtaking GSK's (GSK.L), opens ...

Eli Lilly's ( LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, surpassing GSK's ( GSK) antibiotic, Augmentin, a Reuters report said.